325 related articles for article (PubMed ID: 18283610)
21. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.
May C; Rivella S; Callegari J; Heller G; Gaensler KM; Luzzatto L; Sadelain M
Nature; 2000 Jul; 406(6791):82-6. PubMed ID: 10894546
[TBL] [Abstract][Full Text] [Related]
22. Gene therapy for homozygous beta-thalassemia. Is it a reality?
Boulad F; Rivière I; Sadelain M
Hemoglobin; 2009; 33 Suppl 1():S188-96. PubMed ID: 20001625
[TBL] [Abstract][Full Text] [Related]
23. An in vitro system for efficiently evaluating gene therapy approaches to hemoglobinopathies.
Howrey RP; El-Alfondi M; Phillips KL; Wilson L; Rooney B; Lan N; Sullenger B; Smith C
Gene Ther; 2000 Feb; 7(3):215-23. PubMed ID: 10694798
[TBL] [Abstract][Full Text] [Related]
24. Progress towards hematopoietic stem cell gene therapy.
Kurre P; Kiem HP
Curr Opin Mol Ther; 2000 Aug; 2(4):400-11. PubMed ID: 11249770
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic hemoglobin levels after gene transfer in β-thalassemia mice and in hematopoietic cells of β-thalassemia and sickle cells disease patients.
Breda L; Casu C; Gardenghi S; Bianchi N; Cartegni L; Narla M; Yazdanbakhsh K; Musso M; Manwani D; Little J; Gardner LB; Kleinert DA; Prus E; Fibach E; Grady RW; Giardina PJ; Gambari R; Rivella S
PLoS One; 2012; 7(3):e32345. PubMed ID: 22479321
[TBL] [Abstract][Full Text] [Related]
26. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia.
Sadelain M; Rivière I; Wang X; Boulad F; Prockop S; Giardina P; Maggio A; Galanello R; Locatelli F; Yannaki E
Ann N Y Acad Sci; 2010 Aug; 1202():52-8. PubMed ID: 20712772
[TBL] [Abstract][Full Text] [Related]
27. Lentivirus vectors: difficulties and hopes before clinical trials.
Kafri T
Curr Opin Mol Ther; 2001 Aug; 3(4):316-26. PubMed ID: 11525555
[TBL] [Abstract][Full Text] [Related]
28. [Gene therapy of Gaucher's and Fabry's diseases: current status and prospects].
Fabrega S; Lehn P
J Soc Biol; 2002; 196(2):175-81. PubMed ID: 12360746
[TBL] [Abstract][Full Text] [Related]
29. Development of gene therapy for hemoglobin disorders.
Nienhuis AW; Hanawa H; Sawai N; Sorrentino BP; Persons DA
Ann N Y Acad Sci; 2003 May; 996():101-11. PubMed ID: 12799288
[TBL] [Abstract][Full Text] [Related]
30. Towards the genetic treatment of beta-thalassemia: new disease models, new vectors, new cells.
Moi P; Sadelain M
Haematologica; 2008 Mar; 93(3):325-30. PubMed ID: 18310536
[No Abstract] [Full Text] [Related]
31. Lentivirus vectors in β-thalassemia.
Payen E; Colomb C; Negre O; Beuzard Y; Hehir K; Leboulch P
Methods Enzymol; 2012; 507():109-24. PubMed ID: 22365771
[TBL] [Abstract][Full Text] [Related]
32. Erythropoiesis: Review Article: Slow and Steady Wins The Race? Progress in the Development of Vectors for Gene Therapy of beta-Thalassemia and Sickle Cell Disease.
McInerney JM; Nemeth MJ; Lowrey CH
Hematology; 2000; 4(5):437-455. PubMed ID: 11399586
[TBL] [Abstract][Full Text] [Related]
33. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
[TBL] [Abstract][Full Text] [Related]
34. Gene Addition Strategies for β-Thalassemia and Sickle Cell Anemia.
Dong AC; Rivella S
Adv Exp Med Biol; 2017; 1013():155-176. PubMed ID: 29127680
[TBL] [Abstract][Full Text] [Related]
35. A roadmap to safe, efficient, and stable lentivirus-mediated gene therapy with hematopoietic cell transplantation.
Neschadim A; McCart JA; Keating A; Medin JA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1407-16. PubMed ID: 18022569
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic globin gene delivery using lentiviral vectors.
Rivella S; Sadelain M
Curr Opin Mol Ther; 2002 Oct; 4(5):505-14. PubMed ID: 12435053
[TBL] [Abstract][Full Text] [Related]
37. Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease.
Negre O; Bartholomae C; Beuzard Y; Cavazzana M; Christiansen L; Courne C; Deichmann A; Denaro M; de Dreuzy E; Finer M; Fronza R; Gillet-Legrand B; Joubert C; Kutner R; Leboulch P; Maouche L; Paulard A; Pierciey FJ; Rothe M; Ryu B; Schmidt M; von Kalle C; Payen E; Veres G
Curr Gene Ther; 2015; 15(1):64-81. PubMed ID: 25429463
[TBL] [Abstract][Full Text] [Related]
38. Genetic therapy for beta-thalassemia: from the bench to the bedside.
Arumugam P; Malik P
Hematology Am Soc Hematol Educ Program; 2010; 2010():445-50. PubMed ID: 21239833
[TBL] [Abstract][Full Text] [Related]
39. Engraftment of immune-deficient mice with primitive hematopoietic cells from beta-thalassemia and sickle cell anemia patients: implications for evaluating human gene therapy protocols.
Larochelle A; Vormoor J; Lapidot T; Sher G; Furukawa T; Li Q; Shultz LD; Olivieri NF; Stamatoyannopoulos G; Dick JE
Hum Mol Genet; 1995 Feb; 4(2):163-72. PubMed ID: 7757063
[TBL] [Abstract][Full Text] [Related]
40. In vivo selection to improve gene therapy of hematopoietic disorders.
Persons DA; Nienhuis AW
Curr Opin Mol Ther; 2002 Oct; 4(5):491-8. PubMed ID: 12435051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
